Abstract
Marek’s disease (MD) is a neoplastic disease in chickens causing significant economic losses to the global poultry industry. This study investigates the role of the p53 tumor suppressor gene in MD pathogenesis. Results show a 60% mutation rate in p53 among infected chickens, primarily within the DNA-binding domain. These mutations lead to cytoplasmic accumulation of P53 protein and altered serum levels of P53 antigen and antibodies, suggesting potential for new diagnostic monitoring strategies.
Introduction
Marek’s disease (MD), caused by Marek’s disease virus (MDV), is a major challenge for the poultry sector, leading to tumor formation, paralysis, and immunosuppression. The p53 gene is a critical regulator that prevents cancer by managing the cell cycle and apoptosis. However, mutations can transform p53 from a tumor suppressor into an oncogene, significantly increasing cancer risk. This study explores the frequency and nature of p53 mutations in MD-infected chickens and evaluates serum P53 profiles as a potential diagnostic biomarker.
Methods
The researchers utilized SPF (Specific Pathogen Free) chickens for experimental infection and collected samples from naturally infected clinical cases. RNA was extracted from liver and spleen tissues to analyze the p53 gene. RT-PCR was employed to amplify the p53 DNA-binding domain (DBD) using specific primers and optimized annealing conditions.
Histopathological analysis and immunohistochemistry (IHC) were performed to assess tumor growth and protein localization within tissues. Additionally, serum levels of P53 antigen and antibodies were measured via Enzyme-linked immunosorbent assays (ELISA) to identify systemic markers of infection.
Results
A high mutation rate of 60% (12 out of 20 infected birds) was observed in the p53 gene. These mutations included both point mutations and deletions, predominantly located in the core DNA-binding domain.
Key mutation hotspots were identified at five specific base sites: 651, 786, 828, 864, and 879. Unlike wild-type P53, which is nuclear and degrades rapidly (20–30 minutes), the mutated P53 proteins exhibited a loss of nuclear localization function. This led to significant accumulation in the cytoplasm and a greatly extended half-life of 20–40 hours.
Serological analysis revealed a significant inverse relationship: MD infection led to a decrease in serum P53 antigen levels while triggering a marked increase in P53 antibody titers ($p < 0.01$). This suggests the host immune system mounts a response against the abnormal, accumulated mutant proteins.
Discussion and Conclusion
The study confirms that p53 mutations are a common feature of Marek's disease and likely contribute to its oncogenic progression. The shift of P53 expression to the cytoplasm and the resulting changes in serum antibody profiles provide a promising avenue for MD diagnosis and flock health monitoring. Future research should focus on the specific molecular interactions between MDV genes, such as Meq, and the p53 pathway to fully elucidate the mechanism of viral-induced oncogenesis.
Summary updated